Brain Structure and Function

, Volume 214, Issue 4, pp 303–317

Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages

  • Per Borghammer
  • Mallar Chakravarty
  • Kristjana Yr Jonsdottir
  • Noriko Sato
  • Hiroshi Matsuda
  • Kengo Ito
  • Yutaka Arahata
  • Takashi Kato
  • Albert Gjedde
Review

Abstract

Recent cerebral blood flow (CBF) and glucose consumption (CMRglc) studies of Parkinson’s disease (PD) revealed conflicting results. Using simulated data, we previously demonstrated that the often-reported subcortical hypermetabolism in PD could be explained as an artifact of biased global mean (GM) normalization, and that low-magnitude, extensive cortical hypometabolism is best detected by alternative data-driven normalization methods. Thus, we hypothesized that PD is characterized by extensive cortical hypometabolism but no concurrent widespread subcortical hypermetabolism and tested it on three independent samples of PD patients. We compared SPECT CBF images of 32 early-stage and 33 late-stage PD patients with that of 60 matched controls. We also compared PET FDG images from 23 late-stage PD patients with that of 13 controls. Three different normalization methods were compared: (1) GM normalization, (2) cerebellum normalization, (3) reference cluster normalization (Yakushev et al.). We employed standard voxel-based statistics (fMRIstat) and principal component analysis (SSM). Additionally, we performed a meta-analysis of all quantitative CBF and CMRglc studies in the literature to investigate whether the global mean (GM) values in PD are decreased. Voxel-based analysis with GM normalization and the SSM method performed similarly, i.e., both detected decreases in small cortical clusters and concomitant increases in extensive subcortical regions. Cerebellum normalization revealed more widespread cortical decreases but no subcortical increase. In all comparisons, the Yakushev method detected nearly identical patterns of very extensive cortical hypometabolism. Lastly, the meta-analyses demonstrated that global CBF and CMRglc values are decreased in PD. Based on the results, we conclude that PD most likely has widespread cortical hypometabolism, even at early disease stages. In contrast, extensive subcortical hypermetabolism is probably not a feature of PD.

Keywords

Parkinson’s disease Normalization PET SPECT CBF Glucose 

Supplementary material

429_2010_246_MOESM1_ESM.tiff.
Supplementary material 1 (TIFF 3577 kb)
429_2010_246_MOESM2_ESM.tiff.
Supplementary material 2 (TIFF 3577 kb)

References

  1. Abe Y, Kachi T, Kato T, Arahata Y, Yamada T, Washimi Y, Iwai K, Ito K, Yanagisawa N, Sobue G (2003) Occipital hypoperfusion in Parkinson’s disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 74:419–422CrossRefPubMedGoogle Scholar
  2. Agniel A, Celsis P, Viallard G, Montastruc JL, Rascol O, Demonet JF, Marc-Vergnes JP, Rascol A (1991) Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries. J Neurol Neurosurg Psychiatry 54:783–786CrossRefPubMedGoogle Scholar
  3. Ahl B, Weissenborn K, van den Hoff J, Fischer-Wasels D, Kostler H, Hecker H, Burchert W (2004) Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology 40:73–79CrossRefPubMedGoogle Scholar
  4. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G (2001) Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson’s disease. Neurol Sci 22:45–46CrossRefPubMedGoogle Scholar
  5. Arahata Y, Hirayama M, Ieda T, Koike Y, Kato T, Tadokoro M, Ikeda M, Ito K, Sobue G (1999) Parieto-occipital glucose hypometabolism in Parkinson’s disease with autonomic failure. J Neurol Sci 163:119–126CrossRefPubMedGoogle Scholar
  6. Ben-Shachar D, Bonne O, Chisin R, Klein E, Lester H, Aharon-Peretz J, Yona I, Freedman N (2007) Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: a FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry 31:807–813CrossRefPubMedGoogle Scholar
  7. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, Shing M, Kolbe H, van Den Hoff J, Fricke H, Dengler R, Samii M, Knapp WH (2001) Resting regional cerebral glucose metabolism in advanced Parkinson’s disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 16:1014–1022CrossRefPubMedGoogle Scholar
  8. Bes A, Guell A, Fabre N, Dupui P, Victor G, Geraud G (1983) Cerebral blood flow studied by Xenon-133 inhalation technique in parkinsonism: loss of hyperfrontal pattern. J Cereb Blood Flow Metab 3:33–37PubMedGoogle Scholar
  9. Biesold D, Inanami O, Sato A, Sato Y (1989) Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats. Neurosci Lett 98:39–44CrossRefPubMedGoogle Scholar
  10. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE (1999) Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia. Neurology 52:541–546PubMedGoogle Scholar
  11. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, Vafaee M, Iversen P, Gjedde A (2008) Normalization in PET group comparison studies—the importance of a valid reference region. Neuroimage 40:529–540CrossRefPubMedGoogle Scholar
  12. Borghammer P, Aanerud J, Gjedde A (2009a) Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage 46(4):981–988CrossRefPubMedGoogle Scholar
  13. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A (2009b) Subcortical elevation of metabolism in Parkinson’s disease—a critical reappraisal in the context of global mean normalization. Neuroimage 47(4):1514–1521CrossRefPubMedGoogle Scholar
  14. Borghammer P, Cumming P, Aanerud J, Gjedde A (2009c) Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson’s disease. Neuroimage 45:249–257CrossRefPubMedGoogle Scholar
  15. Borghammer P, Ostergaard K, Cumming P, Gjedde A, Rodell A, Hall N, Chakravarty MM (2009d) A deformation-based morphometry study of patients with early-stage Parkinson’s disease. Eur J Neurol [Epub ahead of print]Google Scholar
  16. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMedGoogle Scholar
  17. Buchsbaum MS, Buchsbaum BR, Hazlett EA, Haznedar MM, Newmark R, Tang CY, Hof PR (2007) Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry 164:1072–1081CrossRefPubMedGoogle Scholar
  18. Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT (2004) Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 127:791–800CrossRefPubMedGoogle Scholar
  19. Cudennec A, Bonvento G, Duverger D, Lacombe P, Seylaz J, MacKenzie ET (1993) Effects of dorsal raphe nucleus stimulation on cerebral blood flow and flow-metabolism coupling in the conscious rat. Neuroscience 55:395–401CrossRefPubMedGoogle Scholar
  20. Dagher A, Nagano-Saito A (2007) Functional and anatomical magnetic resonance imaging in Parkinson’s disease. Mol Imaging Biol 9:234–242CrossRefPubMedGoogle Scholar
  21. Duvernoy HM (1999) The human brain: surface, three-dimensional sectional anatomy with MRI, and blood supply. Springer, ViennaGoogle Scholar
  22. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ (1994) Cortical glucose metabolism in Parkinson’s disease without dementia. Neurobiol Aging 15:329–335CrossRefPubMedGoogle Scholar
  23. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, Eidelberg D (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912–921CrossRefPubMedGoogle Scholar
  24. Eckert T, Van Laere K, Tang C, Lewis DE, Edwards C, Santens P, Eidelberg D (2007) Quantification of Parkinson’s disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 34:496–501CrossRefPubMedGoogle Scholar
  25. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA (1990) The metabolic anatomy of Parkinson’s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5:203–213CrossRefPubMedGoogle Scholar
  26. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S et al (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783–801PubMedGoogle Scholar
  27. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, deLeon D, Bressman SB, Fahn S (1998) Functional brain networks in DYT1 dystonia. Ann Neurol 44:303–312CrossRefPubMedGoogle Scholar
  28. Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, Mentis MJ, Moeller JR, Eidelberg D (2002) Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 17:1265–1270CrossRefPubMedGoogle Scholar
  29. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O’Brien JT (2003) Regional cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage 20:1309–1319CrossRefPubMedGoogle Scholar
  30. Fox PT, Mintun MA, Reiman EM, Raichle ME (1988) Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb Blood Flow Metab 8:642–653PubMedGoogle Scholar
  31. Frisina PG, Haroutunian V, Libow LS (2009) The neuropathological basis for depression in Parkinson’s disease. Parkinsonism Relat Disord 15:144–148CrossRefPubMedGoogle Scholar
  32. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson’s disease. Brain 114(Pt 5):2253–2267CrossRefPubMedGoogle Scholar
  33. German DC, Manaye KF, White CL III, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667–676CrossRefPubMedGoogle Scholar
  34. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD (2002) Monosymptomatic resting tremor and Parkinson’s disease: a multitracer positron emission tomographic study. Mov Disord 17:782–788CrossRefPubMedGoogle Scholar
  35. Globus M, Mildworf B, Melamed E (1985) Cerebral blood flow and cognitive impairment in Parkinson’s disease. Neurology 35:1135–1139PubMedGoogle Scholar
  36. Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, Drzezga A, Stern Y (2008) Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage 40:1503–1515CrossRefPubMedGoogle Scholar
  37. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature clinical practice 4:600–609CrossRefPubMedGoogle Scholar
  38. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84:5976–5980CrossRefPubMedGoogle Scholar
  39. Hosey LA, Thompson JL, Metman LV, van den Munckhof P, Braun AR (2005) Temporal dynamics of cortical and subcortical responses to apomorphine in Parkinson disease: an H2(15)O PET study. Clin Neuropharmacol 28:18–27CrossRefPubMedGoogle Scholar
  40. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ (2000) Cortical dysfunction in non-demented Parkinson’s disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123(Pt 2):340–352CrossRefPubMedGoogle Scholar
  41. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D (2007) Changes in network activity with the progression of Parkinson’s disease. Brain 130:1834–1846CrossRefPubMedGoogle Scholar
  42. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N (1999) SPECT image analysis using statistical parametric mapping in patients with Parkinson’s disease. J Nucl Med 40:1583–1589PubMedGoogle Scholar
  43. Jellinger K (1988) The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 51:540–543CrossRefPubMedGoogle Scholar
  44. Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C, Barre L, Constans JM, Viader F, Eustache F, Desgranges B (2009) Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 30(1):112–124CrossRefPubMedGoogle Scholar
  45. Karbe H, Holthoff V, Huber M, Herholz K, Wienhard K, Wagner R, Heiss WD (1992) Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm Park Dis Dement Sect 4:121–130CrossRefPubMedGoogle Scholar
  46. Kikuchi A, Takeda A, Kimpara T, Nakagawa M, Kawashima R, Sugiura M, Kinomura S, Fukuda H, Chida K, Okita N, Takase S, Itoyama Y (2001) Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson’s disease. J Neurol Sci 193:29–36CrossRefPubMedGoogle Scholar
  47. Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, Herscovitch P, Post RM (2002) Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry 51:237–252CrossRefPubMedGoogle Scholar
  48. Kitamura S, Ujike T, Kuroki S, Sakamoto S, Soeda T, Iio M, Terashi A (1988) Cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. No To Shinkei 40:979–985PubMedGoogle Scholar
  49. Kondo S, Tanaka M, Sun X, Okamoto K, Hirai S (1994) Cerebral blood flow and oxygen metabolism in patients with pure akinesia and progressive supranuclear palsy. Rinsho Shinkeigaku 34:531–537PubMedGoogle Scholar
  50. Kuhl DE, Metter EJ, Riege WH (1984) Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]fluorodeoxyglucose method. Ann Neurol 15:419–424CrossRefPubMedGoogle Scholar
  51. Lacombe P, Sercombe R, Verrecchia C, Philipson V, MacKenzie ET, Seylaz J (1989) Cortical blood flow increases induced by stimulation of the substantia innominata in the unanesthetized rat. Brain Res 491:1–14CrossRefPubMedGoogle Scholar
  52. Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causon R, Jones T, Legg NJ (1985) The effects of l-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. Brain 108(Pt 1):171–191CrossRefPubMedGoogle Scholar
  53. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D (2007) Abnormal metabolic network activity in Parkinson’s disease: test–retest reproducibility. J Cereb Blood Flow Metab 27:597–605CrossRefPubMedGoogle Scholar
  54. Ma Y, Tang C, Moeller JR, Eidelberg D (2009) Abnormal regional brain function in Parkinson’s disease: truth or fiction? Neuroimage 45:260–266CrossRefPubMedGoogle Scholar
  55. Minoshima S, Frey KA, Foster NL, Kuhl DE (1995) Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 19:541–547CrossRefPubMedGoogle Scholar
  56. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K, Kikuchi S, Sasaki H (2005) Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson’s disease with and without dementia, and Alzheimer’s disease. Clin Neurol Neurosurg 107:396–403CrossRefPubMedGoogle Scholar
  57. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA (1987) Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 7:649–658PubMedGoogle Scholar
  58. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, Missimer J, Leenders KL, Eidelberg D (1999) Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264–1269PubMedGoogle Scholar
  59. Montastruc JL, Celsis P, Agniel A, Demonet JF, Doyon B, Puel M, Marc-Vergnes JP, Rascol A (1987) Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson’s disease. Lack of correlation with clinical or neuropsychological improvements. Mov Disord 2:279–289CrossRefPubMedGoogle Scholar
  60. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, Dagher A, Ito K (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64:224–229PubMedGoogle Scholar
  61. Otsuka M, Ichiya Y, Hosokawa S, Kuwabara Y, Tahara T, Fukumura T, Kato M, Masuda K, Goto I (1991) Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson’s disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54:898–904CrossRefPubMedGoogle Scholar
  62. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K (1996) Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson’s disease: a positron emission tomographic study. J Neurol Sci 144:77–83CrossRefPubMedGoogle Scholar
  63. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, Calne DB (1992) Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 49:1262–1268PubMedGoogle Scholar
  64. Perlmutter JS, Raichle ME (1985) Regional blood flow in hemiparkinsonism. Neurology 35:1127–1134PubMedGoogle Scholar
  65. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE (1996) Determination of regional rate constants from dynamic FDG-PET studies in Parkinson’s disease. J Nucl Med 37:1115–1122PubMedGoogle Scholar
  66. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ (1992) Impaired mesial frontal and putamen activation in Parkinson’s disease: a positron emission tomography study. Ann Neurol 32:151–161CrossRefPubMedGoogle Scholar
  67. Powers WJ, Videen TO, Markham J, Black KJ, Golchin N, Perlmutter JS (2008) Cerebral mitochondrial metabolism in early Parkinson’s disease. J Cereb Blood Flow Metab 28:1754–1760CrossRefPubMedGoogle Scholar
  68. Rougemont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y (1984) Local cerebral glucose utilisation in treated and untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 47:824–830CrossRefPubMedGoogle Scholar
  69. Sasaki M, Ichiya Y, Hosokawa S, Otsuka M, Kuwabara Y, Fukumura T, Kato M, Goto I, Masuda K (1992) Regional cerebral glucose metabolism in patients with Parkinson’s disease with or without dementia. Ann Nucl Med 6:241–246CrossRefPubMedGoogle Scholar
  70. Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, Pelton GH, Tabert MH, Honig LS, Moeller JR, Devanand DP, Stern Y (2004) Covariance PET patterns in early Alzheimer’s disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage 23:35–45CrossRefPubMedGoogle Scholar
  71. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4):273–278CrossRefPubMedGoogle Scholar
  72. Spetsieris P, Ma Y, Dhawan V, Moeller JR, Eidelberg D (2006) Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Med Imag 6144:5M1–5M12Google Scholar
  73. Underwood MD, Bakalian MJ, Arango V, Mann JJ (1995) Effect of chemical stimulation of the dorsal raphe nucleus on cerebral blood flow in rat. Neurosci Lett 199:228–230CrossRefPubMedGoogle Scholar
  74. Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R (2004) Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson’s disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 45:933–942PubMedGoogle Scholar
  75. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE (1997) Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med 38:797–802PubMedGoogle Scholar
  76. Videbech P, Ravnkilde B, Pedersen TH, Hartvig H, Egander A, Clemmensen K, Rasmussen NA, Andersen F, Gjedde A, Rosenberg R (2002) The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr Scand 106:35–44CrossRefPubMedGoogle Scholar
  77. Wolfson LI, Leenders KL, Brown LL, Jones T (1985) Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology 35:1399–1405PubMedGoogle Scholar
  78. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC (1996) A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp 4:58–73CrossRefPubMedGoogle Scholar
  79. Worsley KJ, Liao CH, Aston J, Petre V, Duncan GH, Morales F, Evans AC (2002) A general statistical analysis for fMRI data. Neuroimage 15:1–15CrossRefPubMedGoogle Scholar
  80. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, Peters J, Bartenstein P, Lieb K, Schreckenberger M (2009) SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 44:43–50CrossRefPubMedGoogle Scholar
  81. Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, Matsuda H, Yamada M (2005) Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 32:794–805CrossRefPubMedGoogle Scholar
  82. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Per Borghammer
    • 1
    • 2
  • Mallar Chakravarty
    • 3
    • 4
    • 2
  • Kristjana Yr Jonsdottir
    • 3
  • Noriko Sato
    • 5
  • Hiroshi Matsuda
    • 6
  • Kengo Ito
    • 7
  • Yutaka Arahata
    • 7
  • Takashi Kato
    • 7
  • Albert Gjedde
    • 3
    • 2
  1. 1.Department of Nuclear MedicineAarhus University Hospitals, Aarhus Sygehus, NBGAarhusDenmark
  2. 2.PET CentreAarhus University Hospitals, Aarhus Sygehus, NBGAarhusDenmark
  3. 3.Center of Functionally Integrative NeuroscienceUniversity of AarhusAarhusDenmark
  4. 4.Allen Institute for Brain ScienceSeattleUSA
  5. 5.Department of RadiologyNational Center Hospital of Neurology and PsychiatryTokyoJapan
  6. 6.Department of Nuclear MedicineInternational Medical Center, Saitama Medical UniversitySaitamaJapan
  7. 7.Department of Brain Science and Molecular ImagingNational Center for Geriatrics and GerontologyObuJapan

Personalised recommendations